Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS) Research Underfunding Continues
Clicks: 1
ID: 320504
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #347 of 359 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 359 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Polycystic Ovary Syndrome (PCOS), renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), is a common endocrine disorder affecting 4–20% of women worldwide. Prior analysis (2006–2015) demonstrated that PCOS/PMOS received disproportionately less U.S. National Institutes of Health (NIH) funding compared with other chronic disorders of similar prevalence and/or morbidity, namely rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE). A number of bipartisan advocacy efforts have been made since. Objective To determine the impact of current advocacy efforts on NIH funding for PCOS/PMOS research. Methods NIH Research Portfolio Online Reporting Tools were queried. Results In 2016-22 mean annual NIH funding for PCOS/PMOS was $31.8 M vs. $262.4 M (RA), $66.1 M (TB), and $420.4 M (SLE), a 48%, 577%, -15% and 689% difference, respectively, compared to 2006-2015. In 2016-2022 PCOS/PMOS research received 533 awards from 16 NIH Institute/Centers (ICs), with 44.8% of funding arising from the National Institute of Child Health and Human Development (NICHD), compared with 68.4% in the prior study period. RA, TB, and SLE funding came from 27, 36, and 27 ICs, respectively. Conclusions In 2016-2022 PCOS/PMOS research funding by the NIH increased by ∼50% compared to 2006-2015, albeit still less than the increase and total funding for RA and SLE. There appeared to be greater interest in PCOS/PMOS by a higher number of ICs. Recent advocacy efforts appear to be associated with increasing NIH funding. However, much remains to be done to address persistent disparities in research funding for this highly prevalent and morbid women’s health disorder.
| Reference Key |
openalex_W7167883743
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Adrianna N Tilton, Sasha Ottey, William Patterson, Ricardo Azziz |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag272
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.